Article (Scientific journals)
Efficacy and safety of piroxicam revisited. A global meta-analysis of randomised clinical trials.
Richy, F.; Scarpignato, C.; Lanas, A. et al.
2009In Pharmacological Research, 60, p. 254-263
Peer Reviewed verified by ORBi
 

Files


Full Text
Efficacy and safety of piroxicam revisited.pdf
Publisher postprint (1.11 MB)
Request a copy

All documents in ORBi are protected by a user license.

Send to



Details



Abstract :
[en] BACKGROUND: The relative efficacy/safety profiles of traditional (non-selective) NSAIDs (t-NSAIDs) have been repeatedly challenged. To better understand the efficacy and safety profile of piroxicam, a widely used NSAID, a meta-analysis of comparative RCTs was carried out according to the QUOROM guidance. METHODS: A systematic comprehensive research (years 1980-2006) of any comparative randomised controlled trial (of over 7-day duration) with piroxicam for the treatment of osteoarticular conditions was conducted. Conservative analyses were stratified by comparator, outcome, indication, duration, and doses. Publication bias and robustness were exhaustively investigated. RESULTS: Seventy-five comparative trials were ultimately included for analyses. Regarding global efficacy, piroxicam was more effective than naproxen [OR=1.37 (1.05; 1.77)] and nabumetone [OR=1.72 (1.26; 2.34)], while equivalent to other NSAIDS [OR=1.06 (0.96; 1.18)]. For pain and articular swelling, piroxicam was statistically equivalent to all other NSAIDs. For mobility, piroxicam appeared to be more effective than indomethacin, while equivalent to all other NSAIDs. Piroxicam was globally safer than other NSAIDs OR=0.84 [0.73; 0.96], notably indomethacin [OR=0.53 (0.43; 0.64], naproxen [OR=0.75 (0.65; 0.85)] and salicylates [OR=0.36 (0.17; 0.75)]. From a global GI safety point of view, piroxicam was better tolerated than indomethacin [OR=0.46 (0.36; 0.58)], naproxen [OR=0.66 (0.53; 0.83)] and salicylates [OR=0.45 (0.27; 0.78)] while less tolerated when compared to meloxicam [OR=1.49 (1.05; 2.13)]. Major GI effects were comparable among piroxicam users as in comparator drugs users [OR=1.33 (0.96; 1.84)], except for meloxicam [OR=2.37 (1.13; 4.97)]. The skin safety of piroxicam was statistically comparable to those of comparators [OR=1.01 (0.68; 1.51)]. CONCLUSION: This meta-analysis of RCTs support a similar to more favourable efficacy/safety profile of piroxicam as compared to other t-NSAIDs.
Disciplines :
Rheumatology
Author, co-author :
Richy, F.
Scarpignato, C.
Lanas, A.
Reginster, Jean-Yves  ;  Université de Liège - ULiège > Département des sciences de la santé publique > Epidémiologie et santé publique
Language :
English
Title :
Efficacy and safety of piroxicam revisited. A global meta-analysis of randomised clinical trials.
Publication date :
2009
Journal title :
Pharmacological Research
ISSN :
1043-6618
eISSN :
1096-1186
Publisher :
Elsevier, Atlanta, Georgia
Volume :
60
Pages :
254-263
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 27 August 2009

Statistics


Number of views
140 (8 by ULiège)
Number of downloads
2 (1 by ULiège)

Scopus citations®
 
20
Scopus citations®
without self-citations
18
OpenCitations
 
13

Bibliography


Similar publications



Contact ORBi